Hemogenyx plc (AIM: HEMO)*: Secures £3m to accelerate Phase I trials and initiate early commercialisation of HG-CT-1Scancell Holdings plc (AIM: SCLP): Fast track designation for iSCIB1+ in advanced melanoma – Update from the SCOPE Phase II studyPoolbeg Pharma plc (AIM: POLB): 2025 full-year results
28 Apr 2026
SP Angel Healthcare Conditions
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
SP Angel Healthcare Conditions
Scancell Holdings Plc (SCLP:LON), 22.5 | Poolbeg Pharma PLC (POLB:LON), 7.8 | HemoGenyx Pharmaceuticals Plc (HEMO:LON), 745
- Published:
28 Apr 2026 -
Author:
Vadim Alexandre | Greg Pave -
Pages:
4 -
Hemogenyx plc (AIM: HEMO)*: Secures £3m to accelerate Phase I trials and initiate early commercialisation of HG-CT-1Scancell Holdings plc (AIM: SCLP): Fast track designation for iSCIB1+ in advanced melanoma – Update from the SCOPE Phase II studyPoolbeg Pharma plc (AIM: POLB): 2025 full-year results